KYMR Kymera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYMR

Price (delayed)

$37.37

Market cap

$2.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$2.28B

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein ...

Highlights
Kymera Therapeutics's quick ratio has surged by 103% QoQ and by 44% YoY
The equity has soared by 80% from the previous quarter and by 54% YoY
KYMR's net income is down by 5% since the previous quarter but it is up by 2.8% year-on-year
KYMR's debt is up by 27% year-on-year and by 2.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kymeratx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KYMR
Market
Shares outstanding
61.36M
Market cap
$2.29B
Enterprise value
$2.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
33.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.72
Earnings
Revenue
$79.41M
EBIT
-$154.38M
EBITDA
-$150.23M
Free cash flow
-$136.32M
Per share
EPS
-$2.51
Free cash flow per share
-$1.93
Book value per share
$11.64
Revenue per share
$1.12
TBVPS
$12.27
Balance sheet
Total assets
$868.25M
Total liabilities
$157.05M
Debt
$87.02M
Equity
$711.2M
Working capital
$481.12M
Liquidity
Debt to equity
0.12
Current ratio
9.57
Quick ratio
9.38
Net debt/EBITDA
0.08
Margins
EBITDA margin
-189.2%
Gross margin
100%
Net margin
-194.7%
Operating margin
-224.2%
Efficiency
Return on assets
-24%
Return on equity
-31.9%
Return on invested capital
-27%
Return on capital employed
-19%
Return on sales
-194.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
2.95%
1 week
11.99%
1 month
0.65%
1 year
20.94%
YTD
46.78%
QTD
-7.04%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$79.41M
Gross profit
$79.41M
Operating income
-$178.04M
Net income
-$154.59M
Gross margin
100%
Net margin
-194.7%
KYMR's revenue has soared by 70% YoY
KYMR's gross profit has surged by 70% year-on-year
KYMR's net margin is up by 43% year-on-year but it is down by 4.1% since the previous quarter
The operating margin has grown by 38% YoY but it has contracted by 6% from the previous quarter

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
3.21
P/S
33.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.72
The company's EPS rose by 12% YoY
The equity has soared by 80% from the previous quarter and by 54% YoY
The stock's price to book (P/B) is 4% more than its last 4 quarters average of 3.0
KYMR's revenue has soared by 70% YoY
The price to sales (P/S) is 32% higher than the last 4 quarters average of 24.5

Efficiency

How efficient is Kymera Therapeutics business performance
The company's return on sales rose by 43% YoY but it fell by 4.1% QoQ
The return on invested capital has grown by 23% year-on-year and by 6% since the previous quarter
KYMR's return on assets is up by 10% year-on-year and by 5% since the previous quarter
The company's return on equity rose by 8% QoQ and by 6% YoY

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
Kymera Therapeutics's quick ratio has surged by 103% QoQ and by 44% YoY
The current ratio has surged by 102% since the previous quarter and by 44% year-on-year
KYMR's debt is 88% smaller than its equity
The equity has soared by 80% from the previous quarter and by 54% YoY
Kymera Therapeutics's debt to equity has decreased by 43% from the previous quarter and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.